Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Subcutaneous Immune Globulin IgPro20 in Primary Immunodeficiency
2014-003605-15Phase 3
- Sponsor
- CSL Behring
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune serum globulin in Immunogenetic disorder, Primary antibody deficiency (PAD), common variable immunodeficiency (CVID) and 1 more, sponsored by CSL Behring. Primary endpoint: Annualized Rate of Serious Bacterial Infection.
02
Drugs
immune serum globulin
03
Conditions
Immunogenetic disorderPrimary antibody deficiency (PAD)common variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on 2014-003605-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003605-15.